The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
Open accessAbstract
Purpose: Erlotinib is a highly specific epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. This phase II study of erlotinib in patients with HER1/EGFR-expressing non–small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement. Patients and Methods: Fifty-seven patients received an oral, continuous daily dose of 150 mg of erlotinib. Assessments of objective response used WHO and Response Evaluation Criteria in Solid Tumors criteria. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, supplemented with a lung cancer module, Quality of Life Questionnaire LC13, was used to measure health-related quality of life. Additional analyses were performed to identify predictors of response and survival. Results: The objective response rate was 12.3% (95% CI, 5.1% to 23.7%). Responses were observed regardless of type or number of prior chemotherapy regimens. Median survival time was 8.4 months (95% CI, 4.8 to 13.9 months), and the 1-year survival rate was 40% (95% CI, 28% to 54%). Erlotinib therapy was associated with tumor-related symptom improvement. The drug was well tolerated; drug-related cutaneous rash and diarrhea were observed in 75% and 56% of patients, respectively. One patient experienced toxicity consisting of severe grade 3 rash and diarrhea. Time since diagnosis and good performance status were significant predictors of survival in a multivariate Cox proportional hazards model, whereas HER1/EGFR staining intensity was not. Additionally, survival correlated with the occurrence and severity of rash. Conclusion: Erlotinib was active and well tolerated in this patient population, and further clinical development is clearly warranted. Cutaneous rash seems to be a surrogate marker of clinical benefit, but this finding should be confirmed in ongoing and future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Self-citationHidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Self-citationBergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
Gullick, W. J. (1991) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072464 · Cited by 449
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Rusch, V. W., Klimstra, D. S., Venkatraman, E. S., Pisters, P. W. T., Langenfeld, J. E., & Dmitrovsky, E. (1997) · PubMed · Cited by 401
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas.
de Palazzo, I. G., Adams, G. P., Sundareshan, P., Wong, A. J., Testa, J. R., Bigner, D. D., & Weiner, L. M. (1993) · PubMed · Cited by 243
Veale, D., Kerr, N., Gibson, G., Kelly, P., & Harris, A. L. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.306 · Cited by 219
Herndon, J. E., Fleishman, S., Kornblith, A. B., Kosty, M., Green, M. R., & Holland, J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990115)85:2<333::aid-cncr10>3.0.co;2-q · Cited by 193
Ng, S. S. W., Tsao, M., Nicklee, T., & Hedley, D. W. (2002) · PubMed · Cited by 164
Pfeiffer, P., Clausen, P., Andersen, K., & Rose, C. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.320 · Cited by 151
Rusch, V. W., Klimstra, D. S., Linkov, I., & Dmitrovsky, E. (1995) · PubMed · Cited by 150
Modjtahedi, H., & Dean, C. (1994) · International Journal of Oncology · doi:10.3892/ijo.4.2.277 · Cited by 137
The epidermal growth factor receptor as a target for therapy in breast carcinoma
Baselga, J. M., & Mendelsohn, J. M. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666188 · Cited by 133
Reissmann, P. T., Koga, H., Figlin, R. A., Holmes, E. C., & Slamon, D. J. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050243 · Cited by 118
Gore, M. E., Oza, A. M., Rustin, G. J. S., Malfetano, J. H., Calvert, H., Clarke‐Pearson, D. L., Carmichael, J., Ross, G. A., Beckman, R., & Fields, S. Z. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00188-5 · Cited by 106
The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors
Rusch, V. W., Mendelsohn, J. M., & Dmitrovsky, E. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/1359-6101(96)00016-0 · Cited by 101
Naruse, I., Ohmori, T., Ao, Y., Fukumoto, H., Kuroki, T., Mori, M., Saijo, N., & Nishio, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.10173 · Cited by 89
Perez-Soler, R., Kemp, B. L., Wu, Q., Mao, L., Gomez, J. E., Zeleniuch‐Jacquotte, A., Yee, H. T., Lee, J. S., Jagirdar, J. S., & Ling, Y. H. (2000) · PubMed · Cited by 84
Lei, W., Mayotte, J., & Levitt, M. L. (1999) · PubMed · Cited by 64
Statistics in Medical Research
Gehan, E. A., & Lemak, N. A. (1994) · Springer eBooks · doi:10.1007/978-1-4615-2518-9 · Cited by 62
Uncommon Presentations of Hodgkin's Disease
Simpson, L., Taylor, S. G., & Piotrowski, A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.144 · Cited by 59
Targeting the epidermal growth factor receptor for therapy of carcinomas
Davies, D. E., & Chamberlin, S. G. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02232-5 · Cited by 57
Statistics in Medical Research: Developments in Clinical Trials.
Gehan, E. A., & Lemak, N. A. (1996) · Biometrics · doi:10.2307/2532874 · Cited by 30
Newlands, E. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.242 · Cited by 29
Sekine, I., Takami, S., Guang, S. G., et al. (1998) · Oncology Reports · doi:10.3892/or.5.2.351 · Cited by 20
Cited by
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Coudray, N., Ocampo, P. S., Sakellaropoulos, T., Narula, N., Snuderl, M., Fenyö, D., Moreira, A. L., Razavian, N., & Tsirigos, A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0177-5 · Cited by 2,930
Metadata
- Authors
- Pérez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., Rigas, J., Clark, G. M., Santabárbara, P., & Bonomi, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 3238-3247
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2049484790
- Cited by
- 1,070
- References
- 35
- FWCI
- 85.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.